Pharma & Biotech News #PharmaBuzz

Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

Weekly News Recap #Phispers

Merck buys Terns Pharma for US$ 6.7 bn to boost cancer portfolio; Novartis acquires Synnovation unit for up to US$ 3bn

This week’s Phispers is packed with news of drug approvals and M&As. Merck is preparing for its future post-Keytruda pate...

Impressions : 567

FDA approves J&J's plaque psoriasis pill; federal judge blocks key parts of RFK Jr's childhood vaccine policy overhaul

As the war in the Middle East intensifies, the world is facing disruption of major air and sea routes. The war is already disr...

Impressions : 962

Lilly to invest US$ 3 bn in China to boost supply of new obesity drug; Servier acquires Day One Biopharma for US$ 2.5 bn

In Phispers this week, Eli Lilly announced its plans to invest US$ 3 billion in China over the next decade in order to build p...

Impressions : 2211

Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis' dwarfism therapy

Over the past week, tensions in the Middle East have escalated sharply after the US and Israel launched military strikes on Ira...

Impressions : 678

Only few entries up to this point, click to access all

Quality Compliance Alerts #Warning!

All News #Library

Generics

Biotech

APIs

Quality

Sciences

Rare Diseases

Others

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass

Merck buys Terns Pharma for US$ 6.7 bn to boost cancer portfolio; Novartis acquires Synnovation unit for up to US$ 3bn

FDA approves J&J's plaque psoriasis pill; federal judge blocks key parts of RFK Jr's childhood vaccine policy overhaul

Lilly to invest US$ 3 bn in China to boost supply of new obesity drug; Servier acquires Day One Biopharma for US$ 2.5 bn

Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis' dwarfism therapy

Teva's Generics Nintedanib Receives Tentative Approval in US

Glenmark' Generics Nintedanib Receives Tentative Approval in US

Corcept Therap's Lifyorlitm Receives Approval in Us

Encube's Generics Tretinoin Receives Approval in US

Denali's Biologics Avlayah Receives Approval in US

Ascent Pharms' Generics Guanfacine HCl Receives Approval in US

Unique's Generics Bisoprolol Fumarate Receives Approval in US

Zhejiang Jingxin's Generics Ticagrelor Receives Approval in US

Macleods Pharms' Generics Mexiletine HCl Receives Approval in US

Rising's Generics Clindamycin Phosphate Receives Approval in US

4U Health's Receives FDA Warning Letter

Yangzhou H&R Plastic Daily Chemical's Receives FDA Warning Letter

Amneal Issues Voluntary Nationwide Recall of Magnesium Sulfate

Xiamen Kang Zhongyuan Biotech is on FDA Import Alert List

Cardinal Health Issues Voluntary Nationwide Recall of Webcol

Erkul Kozmetik Sanayi is on FDA Import Alert List

Vedic Lifesciences' Receives FDA Warning Letter

OraLabs' Receives FDA Warning Letter

Flowchem Pharma's Receives FDA Warning Letter

Apothecary Pharma's Receives FDA Warning Letter

Rocket Pharma Announces FDA Approval of Kresladi

CVC Capital offers $12.6B to buy out Italian pharma Recordati

Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog

Novo's long-acting insulin Awiqli wins FDA nod

EUROAPI - Availability of 2025 Universal Registration Document

Shreehas Tambe appointed CEO & MD of Biocon, effective April 1

Astrazeneca In Vivo Data Shows Potential, Despite Patient Death

Novartis to buy based biotech firm Excellergy for up to $2 bn

AstraZeneca Drug Reduces COPD Flare ups in Late-stage Trials

Teva's Generics Nintedanib Receives Tentative Approval in US

IMA Seeks Specialist Rx For GLP-1 Misuse Risks

Lupin Gets Tentative FDA Approval for Pitolisant Tablets

GDUFA IV Talks Tackle DMFs, Consultations as Deadline Looms

Weight Loss Drug Market Sees Surge From Pharma Companies

USV Launches 'Usema' To Address India's Metabolic Health Burden

Obesity Bet May Drive Focus On Chronic Segment: Alkem Labs

Novo To Track Generic Surge As Semaglutide Goes Off Patent

Natco Launches Rs 1,290 Semaglutide Following Novo Nordisk

Natco's Rs1,290 Semaglutide Slashes Diabetes Drug Prices in India

Glenmark Pharma launches authorized generic of Savella tablets

Rocket Pharma Announces FDA Approval of Kresladi

Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog

Novo's long-acting insulin Awiqli wins FDA nod

Astrazeneca In Vivo Data Shows Potential, Despite Patient Death

Novartis to buy based biotech firm Excellergy for up to $2 bn

AstraZeneca Drug Reduces COPD Flare ups in Late-stage Trials

Neion Bio Launches With Multi-Biosimilar Partnership

Nucleus Expands Genetic Optimization In India & The Middle East

Nature Cell Advances JointStem Ph3, Nasdaq Roadmap

Beam Base Editor Moves To Pivotal Stage In AATD Data

EMA finalizes guideline on chemistry of active substances

Key Chemical Costs Hinder Drug Ingredient Makers' Production

Piramal Pharma Solutions Marks 20Th Anniversary With Korsch X3

Cambrex Advances US And European Expansions

Wilmington Launches $50M Expansion To Double API Capacity

Drugmakers Seek Price Caps Amid West Asia Conflict Cost Surge

LGM Pharma Invests $15M in Texas, Colorado Facilities

Axplora Invests $60 Million in HPAPI Expansion at Farmabios Site

Propane Shortage Hits Indian Pharma, Endangering Vitamin Output

Rs 600 Cr Pharma Plant Makes Kathua India's Antibiotic Hub

Telangana DCA Issues Safety Advisory On Use Of Semaglutide

Novartis Sued Over Third-Party Data Sharing From Branded Sites

Centre Enhances GLP-1 Drug Oversight Due To Concerns Practices

CSL adds warning to Flucelvax label

GAO calls on FDA to finalize guidance on adcomm COI

DCGI Intensifies Crackdown on GLP-1 Drug Misuse, Misleading Ads

Government Enhances Oversight On Unauthorized GLP-1 Sales

Immunitybio Hit With FDA Warning Letter Over Anktiva Promotions

Lilly Plots European Discontinuations Of Certain Insulin Products

Indian Drugmakers Flood Market With Cheap Ozempic, Wegovy Copies

CMR Surgical Treats 45,000 Patients Worldwide, Enters U.S. Market

Urban India: 20% At Early Heart Risk, 25% Face Respiratory Threat

PhaseV Bringing Integrated AI for Faster Trials to Global Stage